BCTX - BriaCell Therapeutics Corp.

QQQ $ 454.82 $ -2.46 (-0.54 %)

DIA $ 398.57 $ 0.13 (0.04 %)

SPY $ 530.36 $ -0.17 (-0.03 %)

TLT $ 91.26 $ 0.13 (0.14 %)

GLD $ 225.37 $ 0.14 (0.06 %)

Previous Close

$ 1.54

Open

$ 1.43

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 1.43 - $ 1.52

52 Week Range

$ 1.27 - $ 7.18

Volume

169,695

Average Volume

Market Cap

24.61M

Beta (5Y Monthly)

$ 0.36

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	03-18-2024	01-31-2024	10-Q
2	12-14-2023	10-31-2023	10-Q
3	10-25-2023	07-31-2023	10-K
4	06-14-2023	04-30-2023	10-Q
5	03-16-2023	01-31-2023	10-Q
6	12-14-2022	10-31-2022	10-Q
7	10-28-2022	07-31-2022	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

BriaCell Starts Patient Enrollment In Firs...
05/30/2024 12:09:54

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell Therapeutics Announces Clinical S...
05/28/2024 12:28:39

BriaCell Doubles Progression-Free-Survival...
05/24/2024 12:05:28

83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS m...

HC Wainwright & Co. Reiterates Buy on Bria...
05/24/2024 11:24:17

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

BriaCell Therapeutics Announces Pricing Of...
05/15/2024 12:16:40

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell 2024 AACR Preclinical Poster Conf...
04/10/2024 12:10:24

Preclinical data shows that BriaCell's Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via mul...

BriaCell Highlights Data For Antibody-Drug...
04/09/2024 12:49:03

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls i...

BriaCell Receives And Executes Letter Of I...
03/07/2024 13:02:09

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast cancer) and Bria-PROS+...

BriaCell To Present Clinical Data In Centr...
03/06/2024 13:14:01

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell Provides Update On Alleged Illega...
02/27/2024 13:10:39

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage b...

BriaCell Reports Prelim Disease Control Ra...
02/07/2024 13:03:53

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in BriaCell's pivotal ...

Briacell Therapeutics Filed For Mixed Shel...
01/22/2024 22:04:01

-S-3

BriaCell Images Confirm Robust Anti-Tumor ...
01/04/2024 13:46:08

Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associa...

HC Wainwright & Co. Reiterates Buy on Bria...
12/28/2023 16:30:06

HC Wainwright & Co. analyst Emily Bodnar reiterates BriaCell Therapeutics (NASDAQ:BCTX) with a Buy and maintains $18 pri...

BriaCell Reports 71% Central Nervous Syste...
12/28/2023 13:58:25

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clini...

briacell-therapeutics-cancer-drug-shows-preliminary-survival-clinical-benefit-in-pretreated-patients

BriaCell Therapeutics' Cancer Drug Shows P...
12/20/2023 17:37:50

BriaCell Therapeutics Corp (NASDAQ: BCTX) reported preliminary survival and clinical benefit data in a new subset of advanced b...

BriaCell Therapeutics Reports Preliminary ...
12/20/2023 13:42:58

In the subset of Antibody-Drug Conjugate (ADC) refractory patients, Overall Survival (OS) data of BriaCell's combination re...

BriaCell Highlights Outstanding Topline Su...
12/06/2023 14:33:54

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for simil...

BriaCell 2023 SABCS Posters Confirm Activa...
12/06/2023 14:08:07

BriaCell's Bria-IMT™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning &...

BriaCell Reports Unprecedented Anti-Tumor ...
11/03/2023 12:35:55

BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell's next generation breast and...